Sironax Reached Halfway Point in Obesity Drug Trial
The clinical trial is testing the effects of a new NAMPT activator, SIR4156, in combination with semaglutide.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Do you trust that new medical treatments will effectively improve long-term obesity and metabolic health?
Sironax has reached approximately 50 percent of its targeted patient enrollment for the Phase 2 FORGE-LM clinical trial. This study evaluates the combination of the experimental drug SIR4156 and semaglutide in adults with obesity.
Why it matters
Preclinical studies suggest that restoring NAD+ metabolism could provide therapeutic benefits for those managing obesity and metabolic or neuromuscular diseases. The trial aims to assess whether this combination therapy improves body fat mass and composition.
The Phase 2 FORGE-LM study uses a double-blinded, randomized, placebo-controlled, parallel-group design to test SIR4156, an orally active allosteric NAMPT activator. Researchers are measuring body fat mass, lean mass, and patient tolerability.
The players
Sironax
This biotechnology company is headquartered in Waltham, Massachusetts, and focuses on advancing its NAMPT program for metabolic and neuromuscular diseases.
The details
The trial, led by the Waltham-based company Sironax, is specifically examining how SIR4156 performs when combined with semaglutide. Investigators will monitor several secondary objectives, including pharmacokinetics and safety metrics throughout the study duration.
Timeline
October 13, 2026: Sironax announced the completion of 50 percent of patient enrollment.
Health Landscape
This trial follows the development trajectory established by the NAMPT activator research program. The study represents a significant step forward in determining how metabolic restoration therapies compare to current standard-of-care treatments.
This news indicates an ongoing effort to diversify treatment options for adults with obesity by combining new drug candidates with existing therapies. Patients should remain aware that these treatments are currently in the clinical trial phase and are not yet available for public prescription.
The takeaway
The progression of the FORGE-LM trial marks a key milestone in exploring whether NAD+ metabolism restoration can enhance weight loss outcomes. Those interested in clinical research can monitor future updates regarding the study's primary objective of assessing body fat and composition changes.
Further reading
For more information on current treatment trends, visit the Weight Loss section.
Live Poll
Do you trust that new medical treatments will effectively improve long-term obesity and metabolic health?
